comparemela.com
Home
Live Updates
Tecentriq and Zejula Plus Chemo Did Not Offer Better Outcomes in Recurrent Ovarian Cancer : comparemela.com
Tecentriq and Zejula Plus Chemo Did Not Offer Better Outcomes in Recurrent Ovarian Cancer
Treatment with Tecentriq plus Zejula and chemotherapy did not offer better outcomes to patients with recurrent ovarian cancer, according to results from a phase 3 trial.
Related Keywords
Spain
,
Madrid
,
Spanish
,
Antonio Gonzalez Martin
,
Cancer Center Cl
,
Spanish Ovarian Cancer Group
,
Universidad De Navarra
,
News
,
Ovarian Cancer
,
comparemela.com © 2020. All Rights Reserved.